Genmab, J&J in $175M Per Product DuoBody Deal
Genmab A/S entered its second DuoBody deal with a large pharmaceutical firm inside two months. The Copenhagen, Denmark-based antibody developer entered a broad collaboration with the Johnson & Johnson subsidiary Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets. It is banking $3.5 million up front and could receive up to $175 million more in milestone and license payments for each successfully developed product.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST